Systematic treatment of transmissible or non-extremist renal cell cancer (including non-transparent cell renal cancer) includes, inter alia, immunotherapy, target treatment, chemotherapy, biotherapy and treatment of symptoms support. These treatments are described below:
I. Immunotherapy
Immunization treatments attack cancer cells by activation of the patient ‘ s own immune system. Immunization treatment has become an important means of treatment in the treatment of transmissible or non-extractible kidney cell cancer. Common drugs include PD-1 inhibitors and CTLA-4 inhibitors, which can disrupt the expression of PD-1 and CTLA-4 molecules on tumour cells, thus depressing T-cells, re-activating them and attacking tumour cells. Immunization treatment usually takes some time to function and applies to late-transmitted kidney cancers and to non-drive genetic mutations.
II. Target treatment
Target therapy is designed for specific molecular anomalies, which can selectively disrupt the flow of cancer cell growth signals, thus inhibiting the growth and spread of tumours. Target-oriented treatment has been widely applied in the treatment of transmissible or non-extractible kidney cell cancer. Common target drugs include chesamase inhibitors, such as Solafeni, Ivimos, etc. These drugs are mainly administered orally, and blood and organ functions are regularly monitored during treatment. Target treatment has had a significant effect on patients carrying the corresponding genetic mutation and is effective in controlling the growth of transferive kidney cancer cells. III. chemotherapy
chemotherapy is the use of chemical drugs to kill rapidly divided cancer cells. In the treatment of transmissible or non-exposable kidney cell cancer, chemotherapy is usually used as an auxiliary treatment to control local pathologies and to mitigate symptoms. Commonly used chemotherapy drugs include cyclophosphate, Gisitamin, etc., which can be administered through intravenous or oral injection. The length of the course of chemotherapy depends on the progress of the condition and patient tolerance. While chemotherapy does not cure transmissible kidney cancer, it can extend the patient ‘ s life.
IV. Biotherapy
Biotherapy is the use of biological agents artificially synthesized or extracted from natural substances to regulate body immunity responses. Biotherapy also has some application value in the treatment of transmissible or non-extractible kidney cell cancer. Commonly used biological agents include interferant α and white media-2, which can be administered under the skin or intravenously. Biotherapy enhances the body’s anti-oncological immunity response, thus providing some support for the treatment of transitive kidney cancer.
V. Support for treatment of symptoms
The support for treatment aims to alleviate the symptoms of pain and vomiting and to improve the quality of life of patients in the later stages. This includes the use of medications such as painkillers and anti-pull drugs to alleviate the suffering of patients. Analgesics, such as drugs, can be effective in mitigating cancer-related pain; an excretion drug, such as 5-HT3 receptor stress, can help to mitigate the vomiting response from chemotherapy. In addition, non-specific treatments, such as nutritional support and psychological guidance, are included in the treatment of the disease in order to improve the overall situation of patients.
In the light of the above, systematic treatment of transmissible or non-exposable kidney cell cancer requires the development of individualized treatments that take into account the specific circumstances of the patient. A combination of immunotherapy, target treatment, chemotherapy, biotherapy and treatment of disease support can maximize the survival and quality of life of patients.
